Last reviewed · How we verify
LO2A
At a glance
| Generic name | LO2A |
|---|---|
| Sponsor | Ocuwize LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis (PHASE2)
- Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome (PHASE4)
- To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LO2A CI brief — competitive landscape report
- LO2A updates RSS · CI watch RSS
- Ocuwize LTD portfolio CI